| Market Cap | 162.37M | P/E | 46.88 | EPS this Y | - | Ern Qtrly Grth | 3,195.60% |
| Income | 5.51M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -11.00% |
| Sales | 41.08M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -18.00% |
| Dividend | N/A | Price/Book | 4.81 | EPS next 5Y | - | 52W High Chg | -39.00% |
| Recommedations | - | Quick Ratio | 2.87 | Shares Outstanding | 171.42M | 52W Low Chg | 19.00% |
| Insider Own | 43.10% | ROA | 4.77% | Shares Float | 66.03M | Beta | 0.13 |
| Inst Own | 19.74% | ROE | 15.37% | Shares Shorted/Prior | -/- | Price | 0.94 |
| Gross Margin | 54.20% | Profit Margin | 13.42% | Avg. Volume | 26,661 | Target Price | - |
| Oper. Margin | 7.85% | Earnings Date | - | Volume | 18,315 | Change | 0.00% |
Cogstate Limited, a neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research. Its cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. The company is also involved in the design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its technology and associated services are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The company also provides Cognigram, a system for regular and standardized testing to assist primary care physicians and/or hospitals in the early detection of cognitive decline. As of June 30, 2023, it had participated in approximately 1,800 academic research studies and 530 industry sponsored clinical trials. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.
